Skip to content

All Sections

Monday, March 2nd 2026

e-Edition

News
- News
- Crime and Public Safety
- Investigative Reporting
- Election
- Politics
- Health
- Environment
- Business
- Best Reviews
- Jobs
- Housing
- Weather
Local News
Sports
- Sports
- High School Sports
- Chargers
- Rams
- Lakers
- Clippers
- Dodgers
- Angels
- College Sports
- UCLA Sports
- USC Sports
- Kings
- Ducks
- Olympics
- Boxing/MMA
- Soccer
- Horse Racing
Things To Do
Obituaries
Opinion
SCNG Premium
Sponsored Content
Branded Content
- Paid Content by Brandpoint
The T.E.A.
Subscribe
Daily Facts Store
Log In
Logout

Get the latest news delivered daily!

Subscribe
Log In

Account Settings Contact Us Log Out

Spoof a user

Get the latest news delivered daily!

Subscribe
Log In

Redlands Daily Facts

Monday, March 2nd 2026

e-Edition

News
Local News
Sports
Things to Do
Obituaries
Opinion
The T.E.A.

Trending:

Vote for Readers Choice Awards
Weather news
Immigration news
Car rams crowd in Redlands
Lent restaurant offerings 🐟
High school sports

Create Watchlist

Nasdaq Composite

Markets:

News

Ensysce Bioscience Wts (OP:ENSCW)

0.0080 +0.0050 (+166.67%)

Streaming Delayed Price Updated: 10:43 AM EST, Mar 2, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Ensysce Bioscience Wts

< Previous 1 2 Next >

News headline image

Ensysce Biosciences Receives Positive Nasdaq Listing Determination

November 07, 2024

News headline image

Ensysce Biosciences Announces Leadership Team’s Participation in the Annual Pain Therapeutics Summit

October 08, 2024

News headline image

Ensysce Biosciences Provides Shareholder Update, Responds to Recent Shareholder Inquiries

October 02, 2024

News headline image

Ensysce Biosciences Presenting at Upcoming Meetings

September 24, 2024

News headline image

Ensysce Biosciences Posts Video Updates from the IASP World Congress on Pain 2024

September 13, 2024

News headline image

Ensysce Biosciences Provides Mid-Year 2024 Update

July 23, 2024

News headline image

Ensysce Biosciences Hosts IASP 2024 Symposium and Presents Clinical Dataset

July 09, 2024

News headline image

Ensysce Biosciences Announces Partnership to Scale and Manufacture New Drug Candidate

June 25, 2024

News headline image

Ensysce Biosciences Announces Major Milestone for Opioid Use Disorder Program

June 06, 2024

News headline image

Ensysce Biosciences to Participate in the EPHMRA 2024 Annual Meeting

June 03, 2024

News headline image

Ensysce Biosciences Continues Collaboration to Advance the Clinical Development of Innovative Overdose Protection Platform

May 20, 2024

News headline image

Ensysce Biosciences Reports First Quarter 2024 Financial Results

May 13, 2024

News headline image

Ensysce Biosciences' Presentation from the Noble Capital Markets Emerging Growth Virtual Healthcare Equity Conference Published

April 19, 2024

News headline image

Ensysce Biosciences to Participate in the Noble Capital Markets Emerging Growth Virtual Healthcare Equity Conference

April 09, 2024

News headline image

Ensysce Biosciences Announces Publication of Clinical Bioequivalence Manuscript

February 15, 2024

News headline image

Ensysce Biosciences Announces Enrollment Completion for PF614-201 Clinical Study

November 16, 2023

News headline image

Ensysce Biosciences Secures $1.7 Million Convertible Note Financing

October 24, 2023

News headline image

Ensysce Biosciences to Participate in Upcoming Industry Events

June 06, 2023

News headline image

Ensysce Biosciences to Present Groundbreaking Oral Overdose Protection for Opioids at the 5th Annual NIH HEAL Meeting

January 25, 2024

News headline image

Ensysce Biosciences Issues 2024 Shareholder Letter

January 08, 2024

News headline image

Ensysce Biosciences and Quotient Sciences to Present MPAR(R) Overdose Protection Platform at Upcoming CRS 2023 Annual Meeting and Expo

June 27, 2023

News headline image

Ensysce Biosciences Announces the Distribution of Series A Preferred Stock to Holders of Its Common Stock

February 01, 2023

News headline image

Ensysce Biosciences Announces Initiation of Final Stage of Groundbreaking Opioid Overdose Protection Phase 1 Study

January 25, 2023

News headline image

Ensysce Biosciences Announces Successful Completion of Clinical Portion of Oral Human Abuse Potential Trial

January 04, 2023

News headline image

Ensysce Biosciences Announces Data from PF614-MPAR-101-Part A Successfully Demonstrating Opioid Overdose Protection

December 19, 2022

News headline image

Ensysce Biosciences to Present at Diamond Equity Research 2023 Virtual Emerging Growth Invitational

January 23, 2023

News headline image

Ensysce Biosciences Issues 2023 Shareholder Letter

January 11, 2023

News headline image

Ensysce Biosciences Announces Pricing of $4.1 Million Public Offering

December 07, 2022

News headline image

Ensysce Biosciences Announces Completion of Clinical Portion of Overdose Protection Trial PF614-MPAR-101-Part A

December 05, 2022

News headline image

Ensysce Biosciences Reports Third Quarter 2022 Financial Results

November 14, 2022

< Previous 1 2 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

© 2025 FinancialContent. All rights reserved.

Subscribe
Contact Us
About Redlands Daily Facts
Marketplace
Advertising Solutions
Reader Rewards
Subscribe Now

Terms of Use
Cookie Policy
Cookie Preferences
California Notice at Collection
Notice of Financial Incentive
Do Not Sell/Share My Personal Information
Arbitration
Powered by WordPress.com VIP

Copyright 2026 Redlands Daily Facts. All rights reserved. The use of any content on this website for the purpose of training artificial intelligence systems, algorithms, machine learning models, text and data mining, or similar use is strictly prohibited without explicit written consent.